125 related articles for article (PubMed ID: 24183234)
1. Positive correlation between bone marrow mast cell density and ISS prognostic index in patients with multiple myeloma.
Pappa CA; Tsirakis G; Roussou P; Xekalou A; Goulidaki N; Konsolas I; Alexandrakis MG; Stathopoulos EN
Leuk Res; 2013 Dec; 37(12):1628-31. PubMed ID: 24183234
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Mast Cell Density on the Progression of Bone Disease in Multiple Myeloma Patients.
Vyzoukaki R; Tsirakis G; Pappa CA; Devetzoglou M; Tzardi M; Alexandrakis MG
Int Arch Allergy Immunol; 2015; 168(4):263-8. PubMed ID: 26894886
[TBL] [Abstract][Full Text] [Related]
3. High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity.
Devetzoglou M; Vyzoukaki R; Kokonozaki M; Xekalou A; Pappa CA; Papadopoulou A; Alegakis A; Androulakis N; Alexandrakis MG
Tumour Biol; 2015 Nov; 36(11):8491-7. PubMed ID: 26026586
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
5. The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma.
Alexandrakis MG; Passam FH; Dambaki C; Pappa CA; Stathopoulos EN
J Clin Pathol; 2004 Aug; 57(8):856-60. PubMed ID: 15280408
[TBL] [Abstract][Full Text] [Related]
6. Correlation of Mast Cell Density With Angiogenic Cytokines in Patients With Active Multiple Myeloma.
Vyzoukaki R; Tsirakis G; Pappa CA; Androulakis N; Kokonozaki M; Tzardi M; Alexandrakis MG
Clin Ther; 2016 Feb; 38(2):297-301. PubMed ID: 26740291
[TBL] [Abstract][Full Text] [Related]
7. Mast cells influence the proliferation rate of myeloma plasma cells.
Pappa CA; Tsirakis G; Stavroulaki E; Kokonozaki M; Xekalou A; Konsolas I; Alexandrakis MG
Cancer Invest; 2015 Apr; 33(4):137-41. PubMed ID: 25738408
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of bone marrow angiogenesis in multiple myeloma.
Rajkumar SV; Leong T; Roche PC; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR
Clin Cancer Res; 2000 Aug; 6(8):3111-6. PubMed ID: 10955791
[TBL] [Abstract][Full Text] [Related]
9. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
[TBL] [Abstract][Full Text] [Related]
10. Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer.
Chan JK; Magistris A; Loizzi V; Lin F; Rutgers J; Osann K; DiSaia PJ; Samoszuk M
Gynecol Oncol; 2005 Oct; 99(1):20-5. PubMed ID: 16055178
[TBL] [Abstract][Full Text] [Related]
11. Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma.
Fragioudaki M; Tsirakis G; Pappa CA; Aristeidou I; Tsioutis C; Alegakis A; Kyriakou DS; Stathopoulos EN; Alexandrakis MG
Leuk Res; 2012 Aug; 36(8):1004-8. PubMed ID: 22498341
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis and mast cell density in invasive pulmonary adenocarcinoma.
Ullah E; Nagi AH; Lail RA
J Cancer Res Ther; 2012; 8(4):537-41. PubMed ID: 23361271
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.
Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Wellik LA; Fonseca R; Lust JA; Witzig TE; Kyle RA; Greipp PR; Rajkumar SV
Bone Marrow Transplant; 2004 Aug; 34(3):235-9. PubMed ID: 15170170
[TBL] [Abstract][Full Text] [Related]
14. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow angiogenesis in multiple myeloma and its correlation with clinicopathological factors.
Rana C; Sharma S; Agrawal V; Singh U
Ann Hematol; 2010 Aug; 89(8):789-94. PubMed ID: 20177896
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis in multiple myeloma.
Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
[TBL] [Abstract][Full Text] [Related]
17. Assessment of bone marrow fibrosis and angiogenesis in monitoring patients with multiple myeloma.
Babarović E; Valković T; Štifter S; Budisavljević I; Seili-Bekafigo I; Duletić-Načinović A; Lučin K; Jonjić N
Am J Clin Pathol; 2012 Jun; 137(6):870-8. PubMed ID: 22586045
[TBL] [Abstract][Full Text] [Related]
18. Mast cells contribute to vasculogenic mimicry in multiple myeloma.
Nico B; Mangieri D; Crivellato E; Vacca A; Ribatti D
Stem Cells Dev; 2008 Feb; 17(1):19-22. PubMed ID: 18205547
[TBL] [Abstract][Full Text] [Related]
19. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
20. Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance.
Carlini MJ; Dalurzo MC; Lastiri JM; Smith DE; Vasallo BC; Puricelli LI; Lauría de Cidre LS
Hum Pathol; 2010 May; 41(5):697-705. PubMed ID: 20040391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
